Regulation of stem-like CD8+ T cells and their role in immunotherapy
Regulation of stem-like CD8+ T cells and their role in immunotherapy
批准号:
10622463
负责人:
ANA C ANDERSON
金额:
$39.76万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-03-01 至 2026-04-30
关键词:
AffectAntigen-Presenting CellsAntitumor ResponseBiologyCD8-Positive T-LymphocytesCD8B1 geneCTLA4 geneCancer PatientCell CommunicationCell physiologyCellsClinicalCommunicationDataDendritic CellsExhibitsGenerationsGenesGenomicsGoalsHumanImmuneImmunotherapyInflammatoryKnockout MiceKnowledgeLicensingMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMediatorMemoryModificationMorbidity - disease rateMusOutcomePatientsPhenotypePlayPopulationPositioning AttributeProductionProductivityRNARegulationRenal carcinomaReporterReportingRoleSamplingT cell responseT-LymphocyteTCF Transcription FactorTechnologyTestingTumor AntigensTumor TissueTumor-Infiltrating Lymphocytescancer therapycancer typecheckpoint receptorscytokinecytotoxicityexhaustgain of functiongenome editingimmune checkpointimmune checkpoint blockadeimprovedintercellular communicationloss of functionmelanomamortalityneoplastic cellnovelprogrammed cell death protein 1receptor expressionresponsestemstem cellssuccesstooltranscriptomicstreatment responsetumortumor microenvironment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Immune checkpoint receptors (e.g. CTLA-4, PD-1, Tim-3) are expressed on dysfunctional or “exhausted” CD8+
tumor-infiltrating lymphocytes (TILs) that exhibit defective effector functions (cytotoxicity and pro-inflammatory
cytokine production) and are thus poor mediators of tumor clearance. In the last decade, immune checkpoint
blockade (ICB) has achieved durable responses in many cancers, including melanoma, lung, and renal cancer.
Despite this success, current estimates indicate that only 12% of all cancer patients respond to ICB. These
observations underscore the remaining unmet clinical need in cancer treatment and the need to understand what
constitutes effective response to ICB in order to improve response rates.
Through examination of the population and single-cell RNA profiles of CD8+ TILs upon ICB, we have identified
stem-like CD8+ TILs that are integral for the response to ICB. These cells are tumor antigen-specific, exhibit
polyfunctional effector capacity, and increase in proportion upon various ICBs across different cancer types.
Although the transcription factor TCF-1 plays an important role in the maintenance and effector function of these
cells, we have found that TCF-1 expression in CD8+ T cells is not requisite for positive response to ICB in all
tumor contexts. These observations underscore the relevance of stem-like CD8+ TILs for effective response to
ICB and the need to better understand how TCF-1 and additional factors regulate their biology.
Stem cells reside in niches where crosstalk between stem cells and other cells in the niche regulates not only
their maintenance and function but also the function of niche cells. We have found that tumor-associated dendritic
cells (DCs) are altered when TCF-1 is absent in mature CD8+ T cells. We thus hypothesize that 1) stem-like
CD8+ TILs reside within niches in the tumor micro-environment (TME) where they interact with and modulate
antigen-presenting cells; 2) this intercellular communication circuit within the niche may be required for effective
priming of anti-tumor T cell responses; and 3) modulation of stem-like CD8+ TILs may positively or negatively
influence this communication circuit, thus affecting the efficacy of ICB.
Our overarching goal is to understand the cell-autonomous regulation of stem-like CD8+ TILs, their
crosstalk with other cells in the TME, and how together they govern the activation of proficient anti-
tumor CD8+ T cell responses and ICB efficacy. Accordingly, we propose the following aims: 1) Determine the
role of TCF-1 in the generation of proficient anti-tumor T cell responses; 2) Test the role of novel candidate
regulators of stem- and effector-like CD8+ TILs, and 3) Characterize the crosstalk between stem-like CD8+ TILs
and the TME.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1126/sciimmunol.abb9726
发表时间:
2020-11-06
期刊:
Science immunology
影响因子:
24.8
作者:
[Escobar G, Mangani D, Anderson AC]
通讯作者:
Anderson AC
DOI:
10.1038/s41467-017-00608-2
发表时间:
2017-09-19
期刊:
Nature communications
影响因子:
16.6
作者:
[Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L]
通讯作者:
Zitvogel L
DOI:
10.1016/j.cell.2016.08.052
发表时间:
2016-09-08
期刊:
CELL
影响因子:
64.5
作者:
[Singer, Meromit, Wang, Chao, Cong, Le, Marjanovic, Nemanja D., Kowalczyk, Monika S., Zhang, Huiyuan, Nyman, Jackson, Sakuishi, Kaori, Kurtulus, Sema, Gennert, David, Xia, Junrong, Kwon, John Y. H., Nevin, James, Herbst, Rebecca H., Yanai, Itai, Rozenblatt-Rosen, Orit, Kuchroo, Vijay K., Regev, Aviv, Anderson, Ana C.]
通讯作者:
Anderson, Ana C.
DOI:
10.4049/jimmunol.1700407
发表时间:
2018-04-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, Kurtulus S, Kassam N, Sobel RA, Fukumura D, Jain RK, Anderson AC, Kuchroo VK, Joller N]
通讯作者:
Joller N
A TCF1:Glucocorticoid regulatory circuit controls IL-23-driven Th17 pathogenicity
-
批准号:10635984
-
项目类别:
-
资助金额:$51.8万
-
财政年份:2023
-
负责人:ANA C ANDERSON
-
依托单位:
Role of metabolic crosstalk in determining immunity during tumor progression
-
批准号:10718070
-
项目类别:
-
资助金额:$51.39万
-
财政年份:2023
-
负责人:ANA C ANDERSON
-
依托单位:
Steroid hormone regulation of immune responses
-
批准号:10189531
-
项目类别:
-
资助金额:$38.4万
-
财政年份:2018
-
负责人:ANA C ANDERSON
-
依托单位:
Steroid hormone regulation of immune responses
-
批准号:10418699
-
项目类别:
-
资助金额:$37.63万
-
财政年份:2018
-
负责人:ANA C ANDERSON
-
依托单位:
Role of Tim-3 in determining T cell immunity
-
批准号:9024492
-
项目类别:
-
资助金额:$37.77万
-
财政年份:2015
-
负责人:ANA C ANDERSON
-
依托单位:
Regulation of stem-like CD8+ T cells and their role in immunotherapy
-
批准号:10400137
-
项目类别:
-
资助金额:$40.34万
-
财政年份:2015
-
负责人:ANA C ANDERSON
-
依托单位:
Role of Tim-3 in determining T cell immunity
-
批准号:9210064
-
项目类别:
-
资助金额:$37.77万
-
财政年份:2015
-
负责人:ANA C ANDERSON
-
依托单位:
Regulation of stem-like CD8+ T cells and their role in immunotherapy
-
批准号:10211084
-
项目类别:
-
资助金额:$41.16万
-
财政年份:2015
-
负责人:ANA C ANDERSON
-
依托单位:
Genetic Elements that Influence Susceptibility to CNS Autoimmunity
-
批准号:7371005
-
项目类别:
-
资助金额:$17.79万
-
财政年份:2006
-
负责人:ANA C ANDERSON
-
依托单位:
Genetic Elements that Influence Susceptibility to CNS Autoimmunity
-
批准号:7176038
-
项目类别:
-
资助金额:$17.7万
-
财政年份:2006
-
负责人:ANA C ANDERSON
-
依托单位:
Genetic Elements that Influence Susceptibility to CNS Autoimmunity
-
批准号:7758253
-
项目类别:
-
资助金额:$17.98万
-
财政年份:2006
-
负责人:ANA C ANDERSON
-
依托单位:
Genetic Elements that Influence Susceptibility to CNS Autoimmunity
-
批准号:7027146
-
项目类别:
-
资助金额:$17.61万
-
财政年份:2006
-
负责人:ANA C ANDERSON
-
依托单位:
Genetic Elements that Influence Susceptibility to CNS Autoimmunity
-
批准号:7563936
-
项目类别:
-
资助金额:$17.88万
-
财政年份:2006
-
负责人:ANA C ANDERSON
-
依托单位:
The Role of Numb in Lymphocyte Development
-
批准号:6511641
-
项目类别:
-
资助金额:$4.42万
-
财政年份:2002
-
负责人:ANA C ANDERSON
-
依托单位:
The Role of Numb in Lymphocyte Development
-
批准号:6405154
-
项目类别:
-
资助金额:$3.48万
-
财政年份:2001
-
负责人:ANA C ANDERSON
-
依托单位:
海外基金